Share:
Secondary endpoint data for once-nightly FT218 further supports previously announced topline data demonstrating clinically meaningful results at 6 g, 7.5 g, and 9 g doses
DUBLIN, Ireland, April 17, 2021 (GLOBE NEWSWIRE) Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate (ON-SXB) for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy, today announced the presentation of positive secondary endpoint data at the 2021 American Academy of Neurology Annual (AAN) Meeting being held virtually from April 17-22, 2021. FT218 is currently under review at the U.S. Food and Drug Administration with a Prescription Drug User Fee Act (PDUFA) target date of October 15, 2021.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium .
Avadel Pharmaceuticals plcApril 17, 2021 GMT
Secondary endpoint data for once-nightly FT218 further supports previously announced topline data demonstrating clinically meaningful results at 6 g, 7.5 g, and 9 g doses
DUBLIN, Ireland, April 17, 2021 (GLOBE NEWSWIRE) Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate (ON-SXB) for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy, today announced the presentation of positive secondary endpoint data at the 2021 American Academy of Neurology Annual (AAN) Meeting being held virtually from April 17-22, 2021. FT218 is currently under review at the U.S. Food and Drug Administration with a Prescription Drug User Fee Act (PD
Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology Annual Meeting globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
‘Radiologist of the Millennium’ Dr Kakarla Subba Rao leaves a legacy behind
By M Somasekhar| Updated: 16th April 2021 3:38 pm IST
It was locally known as the ‘Bokkala Dhawakhana’ or the hospital for bones in the 1970’s. By the turn of the century it emerged as one of the top super specialty hospitals in the country. The transition Nizam’s Orthopedic hospital into the Nizam’s Institute of Medical Sciences(NIMS) is an exemplary story.
Playing a significant part in shaping this makeover was Dr Kakarla Subba Rao, a noted Radiologist. He oversaw the change, growth and diversification in the mid 1980s with a tough, no-nonsense and committed attitude. Today, the NIMS is a huge facility with expertise and research capabilities in almost all disciplines of modern healthcare.